Grey Fox Wealth Advisors LLC Sells 167 Shares of Gilead Sciences, Inc. (NASDAQ:GILD)

Grey Fox Wealth Advisors LLC decreased its holdings in shares of Gilead Sciences, Inc. (NASDAQ:GILD) by 5.0% during the fourth quarter, according to its most recent disclosure with the SEC. The fund owned 3,163 shares of the biopharmaceutical company’s stock after selling 167 shares during the period. Grey Fox Wealth Advisors LLC’s holdings in Gilead Sciences were worth $256,000 at the end of the most recent quarter.

A number of other large investors have also modified their holdings of GILD. Cornell Pochily Investment Advisors Inc. lifted its holdings in Gilead Sciences by 12.6% in the fourth quarter. Cornell Pochily Investment Advisors Inc. now owns 14,708 shares of the biopharmaceutical company’s stock valued at $1,192,000 after acquiring an additional 1,642 shares during the period. Procyon Advisors LLC grew its holdings in Gilead Sciences by 4.4% in the 4th quarter. Procyon Advisors LLC now owns 30,277 shares of the biopharmaceutical company’s stock valued at $2,453,000 after buying an additional 1,263 shares in the last quarter. Planned Solutions Inc. purchased a new stake in Gilead Sciences in the 4th quarter valued at $182,000. Tectonic Advisors LLC grew its holdings in shares of Gilead Sciences by 6.2% during the 4th quarter. Tectonic Advisors LLC now owns 49,865 shares of the biopharmaceutical company’s stock worth $4,040,000 after purchasing an additional 2,903 shares during the period. Finally, Twin Peaks Wealth Advisors LLC purchased a new position in shares of Gilead Sciences during the 4th quarter worth $259,000. Hedge funds and other institutional investors own 83.67% of the company’s stock.

Wall Street Analyst Weigh In

A number of equities analysts recently commented on GILD shares. Truist Financial cut Gilead Sciences from a “buy” rating to a “hold” rating and lowered their target price for the company from $91.00 to $82.00 in a report on Thursday, February 22nd. StockNews.com upgraded Gilead Sciences from a “buy” rating to a “strong-buy” rating in a research note on Tuesday. Barclays dropped their target price on Gilead Sciences from $85.00 to $80.00 and set an “equal weight” rating on the stock in a report on Monday, February 12th. Cantor Fitzgerald dropped their target price on Gilead Sciences from $80.00 to $78.00 and set a “neutral” rating on the stock in a report on Wednesday, February 7th. Finally, Wells Fargo & Company dropped their target price on Gilead Sciences from $84.00 to $77.00 and set an “equal weight” rating on the stock in a report on Monday, March 4th. One research analyst has rated the stock with a sell rating, nine have assigned a hold rating, five have issued a buy rating and one has given a strong buy rating to the company’s stock. According to data from MarketBeat.com, the company currently has a consensus rating of “Hold” and a consensus target price of $85.36.

Gilead Sciences Price Performance

GILD traded up $0.51 during trading on Thursday, reaching $73.52. 1,969,193 shares of the stock were exchanged, compared to its average volume of 7,505,220. The company has a debt-to-equity ratio of 1.08, a current ratio of 1.43 and a quick ratio of 1.27. Gilead Sciences, Inc. has a 1 year low of $71.37 and a 1 year high of $87.86. The business’s 50 day moving average price is $75.38 and its two-hundred day moving average price is $77.32. The company has a market capitalization of $91.54 billion, a price-to-earnings ratio of 16.38, a P/E/G ratio of 0.92 and a beta of 0.18.

Gilead Sciences (NASDAQ:GILD) last issued its quarterly earnings data on Tuesday, February 6th. The biopharmaceutical company reported $1.72 earnings per share (EPS) for the quarter, missing the consensus estimate of $1.76 by ($0.04). Gilead Sciences had a net margin of 20.89% and a return on equity of 38.85%. The company had revenue of $7.12 billion during the quarter, compared to analysts’ expectations of $7.10 billion. During the same quarter in the prior year, the company earned $1.67 earnings per share. The firm’s revenue was down 3.7% compared to the same quarter last year. As a group, equities research analysts anticipate that Gilead Sciences, Inc. will post 7.07 earnings per share for the current year.

Gilead Sciences Increases Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Thursday, March 28th. Stockholders of record on Friday, March 15th will be given a $0.77 dividend. This is an increase from Gilead Sciences’s previous quarterly dividend of $0.75. This represents a $3.08 annualized dividend and a dividend yield of 4.19%. The ex-dividend date of this dividend is Thursday, March 14th. Gilead Sciences’s dividend payout ratio is currently 68.44%.

Insider Activity

In related news, insider Merdad Parsey sold 2,000 shares of the stock in a transaction dated Wednesday, February 28th. The stock was sold at an average price of $73.18, for a total transaction of $146,360.00. Following the transaction, the insider now directly owns 100,936 shares in the company, valued at $7,386,496.48. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. In related news, CFO Andrew D. Dickinson sold 5,000 shares of the stock in a transaction dated Tuesday, January 16th. The stock was sold at an average price of $85.78, for a total transaction of $428,900.00. Following the transaction, the chief financial officer now directly owns 101,534 shares in the company, valued at $8,709,586.52. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, insider Merdad Parsey sold 2,000 shares of the stock in a transaction dated Wednesday, February 28th. The stock was sold at an average price of $73.18, for a total value of $146,360.00. Following the transaction, the insider now owns 100,936 shares in the company, valued at $7,386,496.48. The disclosure for this sale can be found here. Insiders have sold 15,242 shares of company stock worth $1,277,726 over the last three months. 0.16% of the stock is currently owned by corporate insiders.

Gilead Sciences Company Profile

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.